Psilocybin by Filament Health for Treatment Resistant Depression: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Psilocybin overview

Psilocybin (PEX010) is under development for the treatment of major depressive disorder, methamphetamine use disorder, alcohol use disorder, cancer-related anxiety, depression, opium dependence, treatment resistant depression, mild cognitive impairment, chronic pain, substance use disorders including opioid use disorder (OUD) and eating disorders. It is administered through oral route in the form of capsule. The drug candidate is a tryptamine alkaloid psychedelic which acts by targeting 5-hydroxytryptamine receptor 1A (5HT1A) and 5-hydroxytryptamine receptor 2A (HTR2A) receptors.

Filament Health overview

Filament Health is a natural psychedelic drug development company that discovery and develops natural psychedelic medicines. Filament Health is headquartered in Vancouver, British Columbia, Canada.

For a complete picture of Psilocybin’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.